Results 71 to 80 of about 852 (150)
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 11, Page 1727-1730, November 2025.
wiley +1 more source
Journal of Translational MedicineObjective To explore the correlation between asthma risk and genetic variants affecting the expression or function of lipid-lowering drug targets. Methods We conducted Mendelian randomization (MR) analyses using variants in several genes associated with ...
Yue Zhang +4 more
doaj +1 more source
Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Journal of Lipid and AtherosclerosisApolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) inhibit lipolysis by lipoprotein lipase and may influence the secretion and uptake of various lipoproteins.
Brian Tomlinson +3 more
doaj +1 more source
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
American Journal of Preventive CardiologyThere is a direct relationship between the duration and level of exposure to low density lipoprotein cholesterol (LDL-C) levels over one's lifespan and cardiovascular events.
Maya Safarova +7 more
doaj +1 more source
American Journal of Preventive CardiologyCumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk.
Omar Mhaimeed +5 more
doaj +1 more source
Evinacumab - a new drug in the treatment of homozygous familial hypercholesterolaemia [PDF]
Integrative Cancer Science and Therapeutics, 2021 Stanisław Surma +2 more
openaire +2 more sources
New insights into the treatment of hyperlipidemia: An expert review
Tungs’ Medical JournalThe treatment of hyperlipidemia has been established to reduce the development and progression of atheroma and thereby reduce atherosclerotic cardiovascular disease events.
Brian Tomlinson
doaj +1 more source
Familial hypercholesterolemia: state-of-the-art
Global CardiologyFamilial hypercholesterolemia (FH) affects about 20 million people worldwide and remains markedly underdiagnosed and undertreated. Contemporary studies estimate the prevalence of heterozygous FH (HeFH) at 1 in 192 to 1 in 310, and the prevalence of ...
Ahmed Kamal Siddiqi +7 more
doaj +1 more source
Evinacumab in patients aged 5–17 years with homozygous familial hypercholesterolemia
AtherosclerosisChildren and adolescents with homozygous familial hypercholesterolemia (HoFH) routinely require advanced lipid-lowering therapies (LLTs). We assess the long-term efficacy and safety of evinacumab, a novel LLT, in children and adolescents with HoFH.Study 17100 (NCT04233918) was a phase 3, single-arm, open-label study enrolling 20 children aged 5-11 ...
Robert S. Rosenson +14 more
openaire +3 more sources